vs

Side-by-side financial comparison of agilon health, inc. (AGL) and Roper Technologies (ROP). Click either name above to swap in a different company.

Roper Technologies is the larger business by last-quarter revenue ($2.1B vs $1.6B, roughly 1.3× agilon health, inc.). Roper Technologies runs the higher net margin — 15.8% vs -12.0%, a 27.8% gap on every dollar of revenue. On growth, Roper Technologies posted the faster year-over-year revenue change (11.3% vs 3.1%). Roper Technologies produced more free cash flow last quarter ($507.0M vs $-23.5M). Over the past eight quarters, Roper Technologies's revenue compounded faster (10.5% CAGR vs -1.1%).

agilon health, inc. is a U.S.-based healthcare company partnering with primary care providers to deliver value-based care solutions mainly for senior Medicare beneficiaries. It offers administrative support, clinical tools and risk management frameworks to help physicians improve patient outcomes and cut care costs, operating across over 20 U.S. states.

AGL vs ROP — Head-to-Head

Bigger by revenue
ROP
ROP
1.3× larger
ROP
$2.1B
$1.6B
AGL
Growing faster (revenue YoY)
ROP
ROP
+8.2% gap
ROP
11.3%
3.1%
AGL
Higher net margin
ROP
ROP
27.8% more per $
ROP
15.8%
-12.0%
AGL
More free cash flow
ROP
ROP
$530.5M more FCF
ROP
$507.0M
$-23.5M
AGL
Faster 2-yr revenue CAGR
ROP
ROP
Annualised
ROP
10.5%
-1.1%
AGL

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
AGL
AGL
ROP
ROP
Revenue
$1.6B
$2.1B
Net Profit
$-188.9M
$331.0M
Gross Margin
69.4%
Operating Margin
-12.3%
27.2%
Net Margin
-12.0%
15.8%
Revenue YoY
3.1%
11.3%
Net Profit YoY
-78.5%
53.7%
EPS (diluted)
$4.87

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AGL
AGL
ROP
ROP
Q1 26
$2.1B
Q4 25
$1.6B
$2.1B
Q3 25
$1.4B
$2.0B
Q2 25
$1.4B
$1.9B
Q1 25
$1.5B
$1.9B
Q4 24
$1.5B
$1.9B
Q3 24
$1.5B
$1.8B
Q2 24
$1.5B
$1.7B
Net Profit
AGL
AGL
ROP
ROP
Q1 26
$331.0M
Q4 25
$-188.9M
$428.4M
Q3 25
$-110.2M
$398.5M
Q2 25
$-104.4M
$378.3M
Q1 25
$12.1M
$331.1M
Q4 24
$-105.8M
$462.3M
Q3 24
$-117.6M
$367.9M
Q2 24
$-30.7M
$337.1M
Gross Margin
AGL
AGL
ROP
ROP
Q1 26
69.4%
Q4 25
69.5%
Q3 25
69.5%
Q2 25
69.2%
Q1 25
68.7%
Q4 24
68.3%
Q3 24
69.2%
Q2 24
69.5%
Operating Margin
AGL
AGL
ROP
ROP
Q1 26
27.2%
Q4 25
-12.3%
28.6%
Q3 25
-9.1%
28.4%
Q2 25
-8.3%
28.2%
Q1 25
-1.4%
27.9%
Q4 24
-7.1%
28.0%
Q3 24
-9.2%
28.1%
Q2 24
-2.9%
28.8%
Net Margin
AGL
AGL
ROP
ROP
Q1 26
15.8%
Q4 25
-12.0%
20.8%
Q3 25
-7.7%
19.8%
Q2 25
-7.5%
19.5%
Q1 25
0.8%
17.6%
Q4 24
-6.9%
24.6%
Q3 24
-8.1%
20.8%
Q2 24
-2.1%
19.6%
EPS (diluted)
AGL
AGL
ROP
ROP
Q1 26
$4.87
Q4 25
$3.97
Q3 25
$3.68
Q2 25
$3.49
Q1 25
$3.06
Q4 24
$4.29
Q3 24
$3.40
Q2 24
$3.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AGL
AGL
ROP
ROP
Cash + ST InvestmentsLiquidity on hand
$173.7M
$382.9M
Total DebtLower is stronger
$35.0M
$9.7B
Stockholders' EquityBook value
$126.7M
$18.8B
Total Assets
$1.3B
$34.6B
Debt / EquityLower = less leverage
0.28×
0.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AGL
AGL
ROP
ROP
Q1 26
$382.9M
Q4 25
$173.7M
$297.4M
Q3 25
$171.7M
$320.0M
Q2 25
$171.4M
$242.4M
Q1 25
$136.9M
$372.8M
Q4 24
$188.2M
$188.2M
Q3 24
$148.2M
$269.6M
Q2 24
$109.5M
$251.5M
Total Debt
AGL
AGL
ROP
ROP
Q1 26
$9.7B
Q4 25
$35.0M
$9.3B
Q3 25
Q2 25
Q1 25
Q4 24
$7.6B
Q3 24
Q2 24
Stockholders' Equity
AGL
AGL
ROP
ROP
Q1 26
$18.8B
Q4 25
$126.7M
$19.9B
Q3 25
$306.1M
$20.0B
Q2 25
$408.9M
$19.6B
Q1 25
$500.3M
$19.2B
Q4 24
$471.0M
$18.9B
Q3 24
$574.9M
$18.5B
Q2 24
$676.6M
$18.1B
Total Assets
AGL
AGL
ROP
ROP
Q1 26
$34.6B
Q4 25
$1.3B
$34.6B
Q3 25
$1.6B
$34.6B
Q2 25
$1.7B
$33.2B
Q1 25
$1.9B
$31.4B
Q4 24
$1.7B
$31.3B
Q3 24
$2.1B
$31.6B
Q2 24
$2.2B
$29.8B
Debt / Equity
AGL
AGL
ROP
ROP
Q1 26
0.52×
Q4 25
0.28×
0.47×
Q3 25
Q2 25
Q1 25
Q4 24
0.40×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AGL
AGL
ROP
ROP
Operating Cash FlowLast quarter
$-20.5M
Free Cash FlowOCF − Capex
$-23.5M
$507.0M
FCF MarginFCF / Revenue
-1.5%
24.2%
Capex IntensityCapex / Revenue
0.2%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-119.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AGL
AGL
ROP
ROP
Q1 26
Q4 25
$-20.5M
$738.0M
Q3 25
$-18.2M
$869.5M
Q2 25
$-35.1M
$404.1M
Q1 25
$-32.0M
$528.7M
Q4 24
$16.4M
$722.2M
Q3 24
$-7.7M
$755.4M
Q2 24
$-18.7M
$384.1M
Free Cash Flow
AGL
AGL
ROP
ROP
Q1 26
$507.0M
Q4 25
$-23.5M
Q3 25
$-21.3M
Q2 25
$-38.3M
Q1 25
$-35.8M
Q4 24
$13.2M
Q3 24
$-11.2M
Q2 24
$-22.0M
FCF Margin
AGL
AGL
ROP
ROP
Q1 26
24.2%
Q4 25
-1.5%
Q3 25
-1.5%
Q2 25
-2.7%
Q1 25
-2.3%
Q4 24
0.9%
Q3 24
-0.8%
Q2 24
-1.5%
Capex Intensity
AGL
AGL
ROP
ROP
Q1 26
0.5%
Q4 25
0.2%
Q3 25
0.2%
Q2 25
0.2%
Q1 25
0.3%
Q4 24
0.2%
Q3 24
0.2%
Q2 24
0.2%
Cash Conversion
AGL
AGL
ROP
ROP
Q1 26
Q4 25
1.72×
Q3 25
2.18×
Q2 25
1.07×
Q1 25
-2.64×
1.60×
Q4 24
1.56×
Q3 24
2.05×
Q2 24
1.14×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AGL
AGL

Medical Services$1.6B100%
Other Operating$2.5M0%

ROP
ROP

Segment breakdown not available.

Related Comparisons